Table 1.

Clinical features and treatment of 8 patients taking part in the phase I clinical trial

Patient no.	Nationality	Age (years)	Duration (years)	B51 101	Disease manifestations	Disease activity	Immuno- suppressive treatment	Dose of p336-351- CTB	Primary ocular result after all treatment withdrawn
1	Middle eastern (Turkish)	35	4	+	Uveitis, RAS, pustular lesions, arthralgia	Nil	5–7·5 mg Predn. 150 mg Azath.	0·5 mg	No relapse maintained 24 months
2	Caucasian (Irish)	36	13	+	Uveitis, RAS, Genital ulcers, Arthralgia	Nil	10 mg Predn.	5 mg	No relapse maintained 18 months
3	Caucasian (English)	35	1	+	Uveitis RAS Er. Nodosum	Nil	10–15 mg Predn.150 mg Azath.	0·5 mg	Relapse after 10 months
4	Caucasian (Irish)	36	12	+	Uveitis, RAS Genital ulcers,Arthralgia	Nil	10 mg Predn.100 mg Azath.	0·5 mg	Relapse after 1 month
5	Caucasian (English)	30	3	?	Uveitis, RAS,Genital ulcers	Nil	10 mg Predn.1·5 mg Colchicine	5 mg	Relapse after 2 wks
6	Middle Eastern (Iraqi)	51	>13	+	Uveitis, RAS, Foliculitis, Arthralgia, Thrombophlebitis	Nil	5 mg Predn.	0·5 mg	Relapse within 1 day of reducing Predn.
7	Caucasian (English)	29	6	+	Uveitis, RAS, Genital ulcers, Foliculitis	Severe pustules	15 mg Predn.400 mg Cyclosporin	5 mg	Relapse within 2 weeks of reducing Cyclosp.
8	Caucasian (English)	34	6	−	Uveitis, RAS Genital ulcers, Foliculitis, Arthralgia	RAS and Foliculitis	15 mg Predn.2 mg CellCept	5 mg	Relapse within 1 day of reducing Predn.

Predn., Prednisolone; Azath., Azathioprine; Cyclosp., Cyclosporin.